Tropical Medicine and Infectious Disease

To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.

Leishmaniasis is a severe parasitic disease transmitted by sandflies that affects both humans and animals, with clinical manifestations ranging from cutaneous lesions to life-threatening visceral involvement. Current treatments are limited by toxicity, high cost, and the emergence of drug-resistant strains, underscoring the need for safer and more effective therapeutic strategies. In this study, we investigated the antiparasitic potential of combining Amphotericin B, a drug commonly used for leishmaniasis treatment, with 1,10-phenanthroline-5,6-dione (phendione) coordinated to copper (Cu²⁺-phendione), an experimental coordination compound, against Leishmania amazonensis promastigotes. The combination markedly impaired parasite proliferation, disrupted ultrastructural integrity, and interfered with metabolic activity. Mechanistic analyses revealed the presence of autophagosomes and pronounced mitochondrial alterations in treated parasites, suggesting the induction of cellular stress and the disruption of essential survival pathways. In addition, the treatment reduced the association index with THP-1 cells, indicating a decrease in parasite infectivity. Collectively, these findings demonstrate that the combination of Cu²⁺-phendione and Amphotericin B exerts potent antiparasitic effects through multiple mechanisms. Our results also showed that Cu²⁺-phendione combined with AmB displayed an additive effect, although the isobologram suggested that certain ratios approached synergy. The results support the potential of this combination as a novel chemotherapeutic approach against leishmaniasis and provide a basis for future in vivo studies to evaluate safety, efficacy, and optimal dosing strategies.

Chagas disease (CD) remains a major global health challenge and requires standardized, multidisciplinary, and evidence-based clinical approaches. This article aims to present and systematize the model of clinical routines developed at the Clinical Research Laboratory on Chagas Disease (Lapclin-Chagas), INI/Fiocruz, for the initial evaluation and longitudinal follow-up of patients with chronic CD. The proposal is intended to serve as a replicable and adaptable framework for referral centers in both endemic and non-endemic settings. Using a descriptive qualitative design, institutional protocols, national and international guidelines, and expert consultations were analyzed to construct a comprehensive care model. The resulting protocol integrates diagnostic pathways (including dual serological confirmation and clinical staging), criteria for etiological treatment, and coordinated multidisciplinary follow-up involving cardiology, gastroenterology, pharmaceutical care, nutrition, psychology, and social support. Specific pathways are also presented for Trypanosoma cruzi (T. cruzi)/HIV coinfection, laboratory accidents, and monitoring of adverse reactions to benznidazole. By consolidating more than three decades of institutional experience into operational workflows, this proposal offers an innovative contribution to the organization of CD care and provides actionable guidance for health systems seeking to improve diagnostic accuracy, therapeutic adherence, patient safety, and long-term outcomes.